Dr. Cameron trained initially as a pharmacologist at the University of Edinburgh in Scotland which is his home country. He completed postgraduate training in the same discipline at the University of Rochester, then postdoctoral fellowship training in clinical chemistry at the Johns Hopkins Hospital...
Dr. Cameron trained initially as a pharmacologist at the University of Edinburgh in Scotland which is his home country. He completed postgraduate training in the same discipline at the University of Rochester, then postdoctoral fellowship training in clinical chemistry at the Johns Hopkins Hospital, Department of Pathology, in Baltimore.
Dr. Cameron then qualified in medicine at Upstate Medical University in Syracuse, later serving as an internal medicine resident at the New York Presbyterian Hospital-Cornell in New York City. He finally completed a five-year integrated clinical and research fellowship in cardiology and vascular medicine at the University of Rochester. Dr. Cameron was mentored in platelet biology by Dr. Craig Morrell who is a national expert in this discipline. He initiated an innovative vascular assessment referral clinic for local optometrists called Vascular Assessment in Patients for Ocular Reasons (VAPOR). He was also the founding member of the University of Rochester Pulmonary Embolism Response Team (PERT). Dr. Cameron has a clinical and academic interest in thrombotic emergencies and presently serves on the University of Rochester faculty as a physician investigator. He serves as Associate Editor of Vascular Medicine, and he is on the editorial board of ATVB. He is a frequent peer reviewer for Circulation, Circulation Research, Journal of Clinical Investigation, American Journal of Medicine, Journal of Thrombosis and Thrombolysis, and the British Medical Journal. In addition, Dr. Cameron is a test writer for the American Board of Internal Medicine Cardiovascular Disease MOC and longitudinal assessment.
Dr. Cameron specializes in both cardiac and vascular disease with admitting privileges at Strong Memorial Hospital where he cares for patients in the Coronary Care Unit. He has documented COCATS Level II training in echocardiography, nuclear cardiology, and COCATS Level III training in vascular medicine. Dr. Cameron is board certified in Internal Medicine, Vascular Medicine, Vascular Ultrasound, and Cardiovascular Disease.
Faculty Appointments
Adjunct Assistant Professor
-
Department of Medicine, Cardiology (SMD)
Credentials
Post-doctoral Training & Residency
University of Rochester School of Medicine Postdoctoral Fellowship (Basic Research) Laboratory of Dr. Craig Morrell
New York Presbyterian Hospital (Weill-Cornell) Internship and Residency (Internal Medicine)
University of Rochester School of Medicine, Clinical Fellowship (Cardiovascular Disease and Vascular Medicine)
Memorial Sloan Kettering Cancer Center Internship and Residency (Internal Medicine)
Clinical and Research Fellowship in Chemical Pathology (Clinical Chemistry) at the Johns Hopkins Hospital.
Education
MD | SUNY Upstate Medical University.Medicine.2009
PhD | University of Rochester School of Medicine & Dentistry.Pharmacology.2003
MS | University of Rochester School of Medicine & Dentistry.Pharmacology.2001
BSc (Hons) | UK-University of Edinburgh.Pharmacology.1998
Awards
Outstanding Young Alumnus 2019 - Upstate Medical University.2019 - 2019
K Award Grant.2018
Resident Research Mentoring Award.2018
URMC Quality and Safety Certificate of Recognition - Pulmonary Embolism Response Team.2017
Fellow of the American College of Cardiology.2016
Jay D. Coffman MD Young Investigator Award in Vascular Medicine (2nd Place).2016
Fellow of the Society of Vascular Medicine.2016
NIH K08 Career Development Award.2016
Best of AHA Abstracts.2015
Abstract and Travel Award, First Place.2015
Abstract Merit Badge (top 20%).2015
Abstract and Travel Award (top 10%).2015
Platelet Colloquium Career Investigator Award.2015
Society of Vascular Medicine Scholarship.2014
Abstract Award (NY State), Second Place.2014
Postdoctoral Research Award (1st place).2013
NIH LRP (NHLBI).2013 - 2019
Multiple "Strong Star" nominations and Hall of Fame citation from patients and colleagues for exceptional clinical care.2011 - 2012
Hospitalist award for best resident (honorable mention).2011
Herbert Lourie, MD Graduation Award for gentility, thoughtfulness, philanthropy, compassion, commitment to academic excellence..2009
Alpha Omega Alpha Research Award – First Place.2008
American College of Physicians NY Upstate Scientific Conference: First Place.2008
Arnold Gold Humanism Honor Society for excellence in humanistic clinical care, leadership, compassion and dedication to service..2008
Distinguished Abstract Award (top 25 out of 837 selected abstracts).2005
Young Investigator's Award - awarded with distinction.2005
Pathology Young Investigator's Award for excellence in basic research – highest scoring winner.2005
Pathology Young Investigator's Award for excellence in clinical research.2004
Dean's Award for the Most Innovative PhD Thesis.2003
Research
Our laboratory studies signal transduction pathways in the cardiovascular system as they relate to thrombotic and ischemic diseases. Our research focus is mostly basic and translational in nature. We are particularly interested in identifying existing and novel platelet signaling pathways in myoc...
Our laboratory studies signal transduction pathways in the cardiovascular system as they relate to thrombotic and ischemic diseases. Our research focus is mostly basic and translational in nature. We are particularly interested in identifying existing and novel platelet signaling pathways in myocardial ischemia and in peripheral vascular disorders such as advanced peripheral artery disease (PAD), chronic venous insufficiency (CVI), and aortic aneurysmal disease. An overarching theme of our laboratory is personalized medicine where we aim to better define platelet function in disease states, paying close attention to post-receptor signal transduction pathways.
Platelets are small anucleate blood particles which play an important role in thrombosis, hemostasis, and inflammation. When patients are treated with anti-platelet drugs, some do not derive expected benefits or they experience off-target adverse events. We have initiated several lines of investigation that show the megakaryocyte-derived platelet phenotype may be fundamentally different in various diseases.
Project 1: Using a murine model of myocardial infarction, we have shown that platelet RNA and the platelet proteome as well as platelet agonist responsiveness are different in the post-myocardial infarct environment. A career-development grant was awarded to study the role of ERK5 and related protein kinases in changing platelet function in ischemic disease. We began enrolling patients with ST-segment elevation myocardial infarction (STEMI) and non ST-segment elevation myocardial infarction (NSTEMI) in July of 2016 to study this phenomenon immediately when the patient arrives in the emergency department at Strong Memorial Hospital.
Project 2: Using a murine model of abdominal aortic aneurysm (AAA) and, along with our colleagues in vascular surgery and cardiac surgery at the University of Rochester, we are studying platelet function both as a consequence of aortic disease and in promoting aortic disease progression. We use genetic approaches to identify platelet targets useful in modulating vascular disease.
Project 3: Using a murine model of critical limb ischemia (CLI) and various models mimicking the human condition of hypoxia, we have identified two important signal transduction mechanisms which lead to dysregulated platelet behavior. This may in part explain why patients with PAD are predisposed to heart attack and stroke. We recently extended our studies to human platelets from PAD patients with our colleagues in vascular surgery at the University of Rochester and in the Department of Pathology at the Johns Hopkins Hospital.
Project 4: It is well-documented that patients who are exposed to inhaled pollutants are predisposed to adverse cardiovascular events. Using platelets taken from patients with acute myocardial infarction, we are working with our colleagues in environmental medicine and public health at the University of Rochester to study the role of particulate matter and environmental pollutants in changing platelet function and promoting thrombosis. These studies may reveal protective mechanisms that could be employed to prevent adverse cardiac events caused by pollutants.
Project 5: Using our existing database of patients with venous thromboembolism (VTE), we are studying various clinical and translational aspect of high risk pulmonary embolism locally and as part of the National Pulmonary Embolism Response Team (PERT) consortium.
We utilize contemporary cell biology, biochemistry, molecular biology, and animal models to address these questions. Our overall goal is to evaluate gaps in clinical care, identify viable signaling pathways in human tissue for drug intervention, and then finally to utilize animal models to test the working hypothesis. We are a friendly, collaborative laboratory with continuous federal funding from 2016-2026 with a keen interest in the career development of all laboratory members.
Sahai A, *Bhandari B, Koupenova M, Freedman J, *Godwin M, McIntyre M, Chung M, Iskander JP, Kamran H, Hariri E, Aggarwal A, Kalra A, Bartholomew JR, McCrae KR, Elbadawi A, Svensson LG, Kapadia S, Cameron SJ.
Kim BS, Auerbach DA, Sadhra H, Godwin M, Bhandari R, Ling FS, Mohan A, Yule DI, Wagner II L, Rich DQ, Ture SK, Morrell CN, Timpanaro-Perrotta, Younis A, Goldenberg I, Cameron SJ.
Koupenova M, Corkrey HA, Vitseva O, Tanriverdi K, Somasundaran M, Liu P, Soofi S, Bhandari R, Godwin M, Parsi KM, Cousineau A, Maehr R, Wang J, Cameron SJ, Rade JJ, Finberg RW, Freedman JE.
Journal of Thrombosis and Thrombolysis. 2020; 49(1): 34-41.
Fibrosis, Thrombosis, and Dacrocytosis: An Unusual Case of Male Systemic Lupus Erythematosus
Wu MQ, Preslar M, Katerji H, Palma C, Cameron SJ.
American Journal of Medicine. 2020; .
Effect of metabolic syndrome on mean pulmonary arterial pressures in patients with acute pulmonary embolism treated with catheter-directed thrombolysis.
Stewart LK, Beam DM, Casciani T, Cameron SJ, Kline JA.
Bennett J, Mastrangelo M, Ture S, Smith C, Loelius S, Berg R, Shi X, Burke R, Spinelli S, Cameron SJ, Carey T, Brookes P, Gerszten R, Sabater-Lleal M, De Vries P, Huffman J, Smith N, Morrell C, and Lowenstein CJ.
Nature Communications. 2020; .
SARS-CoV-2 and ACE2: The Biology and Clinical Data Behind the ARB and ACEI Controversy.
Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier, AH, Smith JD, Kalra A, Surafel GK, Thomas G, Hawkins ES, Svensson LG.
EBioMedicine. 2020; .
SARS-CoV-2 and Pulmonary Embolism: who stole the platelets?
Tran M, Sheth C , Bhandari R Cameron SJ, Hornacek D.
John A Bennett, Sara K Ture, Rachel A Schmidt, Michael A Mastrangelo, Scott J Cameron, Lara E Terry, David I Yule, Craig N Morrell, and Charles J Lowenstein.
Journal of Pharmacology and Experimental Therapeutics. 2019; 369(2): 182-187.
Beom Soo Kim, David A. Auerbach, Hamza Sadhra, Frederick S. Ling, MD , Sandra Toth, Amy Mohan, Sara Tura, Ilan Goldenberg, David Q. Rich, and Scott J. Cameron.
Cameron SJ, Mix D, Ture S, Schmidt R, Mohan A, Pariser D, Stoner M, Shah P, Chen L, Zhang H, Field DJ, Modjeski KL, Toth S, Morrell CN.
Hypoxia and Ischemia Promote a Maladaptive Platelet
Do elevated blood levels of omega-3 fatty acids modify effects of particulate air pollutants on fibrinogen?
Daniel Patrick Croft, Robert Block,Scott Cameron, Kristin Evans, Charles Lowenstein, Frederick Ling, Wojciech Zareba, Philip Hopke, Mark Utell, Sally Thurston, Kelly Thevenet-Morrison, David Rich.
Platelet CD36 signaling through ERK5 promotes Caspase-Dependent Procoagulant Activity and Fibrin Deposition in Vivo
Moua Yang, Andaleb Kholmukhamedov, Marie L. Schulte, Brian C Cooley, Na'il O Scoggins, Jeremy P Wood, Scott Cameron, Craig N Morrell, Shawn Jobe, and Roy L. Silverstein.
